ClinicalTrials.gg
CompletedNCT07903714Updated Oct 29, 2026

Hyperventilation and Post-Activation Performance Enhancement on Anaerobic Capacity

An interventional study of Voluntary Hyperventilation and Post-Activation Performance Enhancement (PAPE) in Anaerobic Performance, Energy System Contributions and Hyperventilation, sponsored by Manisa Celal Bayar University. Completed at 1 site in Turkey (Türkiye). Open to male participants aged 18 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Manisa Celal Bayar University · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Feb 2026, registered Oct 2026).
Updated Oct 29, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
18 Years to 25 Years
Sex
Male
01

Study summary

The purpose of this study is to investigate the independent and combined effects of post-activation performance enhancement (PAPE) and voluntary hyperventilation (HV) interventions on anaerobic power outputs, energy system contributions during a 30-second Wingate Anaerobic Test (WAnT).

02

Conditions studied

  • Anaerobic Performance
  • Energy System Contributions
  • Hyperventilation
  • Post Activation Potentiation

Browse trials for

03

In context

Hyperventilation

43 studies on the registry are indexed under Hyperventilation; 6 are open to participants now.

This study's enrollment of 11 is below the median of 40 across 31 interventional studies indexed under Hyperventilation.

Browse Hyperventilation studies →

Lead sponsor

Manisa Celal Bayar University is the lead sponsor of 36 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 25 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: - Athletes who did not have any acute or chronic cardiovascular or lung conditions

  • Trained at least three times a week and participated in regular competitions
  • Aged between 18 and 25 years

Exclusion Criteria:

  • Current or recent orthopedic injuries that could negatively affect cycling performance
  • Use of dietary supplements or performance-enhancing substances (e.g., creatine, caffeine, or bicarbonate) within the past four weeks
  • Ongoing medical treatment that could affect metabolic or performance outcomes
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Active comparator
    Control Session

    Baseline 30-s Wingate test without prior intervention.

    Procedure: Wingate Anaerobic Test

  • Experimental
    Hyperventilation (HV) Session

    30-s Wingate test preceded by voluntary hyperventilation.

    Other: Voluntary Hyperventilation · Procedure: Wingate Anaerobic Test

  • Experimental
    PAPE Session

    30-s Wingate test preceded by PAPE protocol.

    Other: Post-Activation Performance Enhancement (PAPE) · Procedure: Wingate Anaerobic Test

  • Experimental
    PAPE+HV Session

    30-s Wingate test preceded by combined PAPE and hyperventilation protocols.

    Other: Voluntary Hyperventilation · Other: Post-Activation Performance Enhancement (PAPE) · Procedure: Wingate Anaerobic Test

Interventions

  • OtherVoluntary Hyperventilation

    Controlled breathing protocol performed prior to testing.

  • OtherPost-Activation Performance Enhancement (PAPE)

    Conditioning protocol applied prior to the Wingate test to potentiate subsequent anaerobic performance.

  • ProcedureWingate Anaerobic Test

    30-second maximal anaerobic cycling test on a cycle ergometer.

06

What researchers measure

Primary outcomes

  1. Relative Peak Power (RPP)

    Evaluation of relative peak power during the 30-second Wingate anaerobic test

    Time frame: During the 30-second Wingate anaerobic test

  2. Relative Mean Power (RMP)

    Evaluation of relative mean power during the 30-second Wingate anaerobic test.

    Time frame: During the 30-second Wingate anaerobic test

  3. Fatigue Index (FI)

    Evaluation of fatigue index during the 30-second Wingate anaerobic test.

    Time frame: During the 30-second Wingate anaerobic test

Secondary outcomes

  1. ATP-PCr Energy System Contribution (Absolute)

    Evaluation of ATP-PCr energy system contribution in absolute terms (kJ), determined from the fast component of excess post-exercise oxygen consumption (EPOC) during recovery.

    Time frame: During the 5-minute post-exercise recovery period

  2. ATP-PCr Energy System Contribution (Relative)

    Evaluation of ATP-PCr energy system contribution in relative terms (%), determined from the fast component of excess post-exercise oxygen consumption (EPOC) during recovery.

    Time frame: During the 5-minute post-exercise recovery period

  3. Glycolytic Energy System Contribution (Absolute)

    Evaluation of glycolytic energy system contribution in absolute terms (kJ), estimated using delta blood lactate concentration (Δ\[BLa\]) measured pre-test and post-test.

    Time frame: Pre-test and at the 5-minute post-test recovery

  4. Glycolytic Energy System Contribution (Relative)

    Evaluation of glycolytic energy system contribution in relative terms (%), estimated using delta blood lactate concentration (Δ\[BLa\]) measured pre-test and post-test.

    Time frame: Pre-test and at the 5-minute post-test recovery

  5. Oxidative Energy System Contribution (Absolute)

    Evaluation of oxidative energy system contribution in absolute terms (kJ), calculated based on net oxygen volume consumed during the 30-second test (VO₂net).

    Time frame: During the 30-second Wingate anaerobic test

  6. Oxidative Energy System Contribution (Relative)

    Evaluation of oxidative energy system contribution in relative terms (%), calculated based on net oxygen volume consumed during the 30-second test (VO₂net).

    Time frame: During the 30-second Wingate anaerobic test

07

Study locations

1 site
  • Manisa Celal Bayar University, Faculty of Sport Sciences
    Manisa, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07903714
Lead sponsor
Manisa Celal Bayar University
Responsible party
Sponsor
First posted
Oct 29, 2026
Start date
Feb 11, 2026
Primary completion
Feb 26, 2026
Completion
Feb 26, 2026
Last update
Oct 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion